Results 81 to 90 of about 160,832 (337)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

A prelude report on molecular docking of HER2 protein towards comprehending anti-cancer properties of saponins from Solanum tuberosum [PDF]

, 2012
Saponins are extensively known for many biological activities e.g. antimicrobial, anti-palatability, anti-cancer and hemolytic. As cancer cells have a more cholesterol-like compound in their membrane structure the saponins bind cholesterol due to their ...
Pratyoosh Shukla, Puneet K. Singh
core   +2 more sources

CSN6 Promotes Pancreatic Cancer Progression and Gemcitabine Resistance via Antagonizing DCAF1‐Mediated Ubiquitination of NPM1

Advanced Science, EarlyView.
COP9 signalosome subunit 6 (CSN6) promotes the auto‐ubiquitination and degradation of DDB1‐CUL4 associated factor 1 (DCAF1), thereby antagonizing DCAF1‐mediated ubiquitination of Nucleophosmin (NPM1). This stabilization of NPM1 enhances the ribosome biogenesis process and the translation of specific gemcitabine‐resistance proteins, ultimately driving ...
Yijing Zhang, Han Gao, Aiwen Tang, Haiwen Lyu, Zongmin Fan, Jiahui Guo, Yuzhi Wang, Hairong Yi, Qihao Pan, Haidan Luo, Baifu Qin, Boyu Zhang, Xiangqi Meng, Qingxin Liu, Mong‐Hong Lee   +14 more
wiley   +1 more source

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj  

Positive Feedback Loop of Histone Lactylation‐Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance

Advanced Science, EarlyView.
Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang, Jiao Chen, En‐Liang Zhu, Ming‐Jian Ma, Yang‐Yin‐Hui Yu, Ying‐Qin Zhu, Jing‐Yuan Ye, Jin‐Zhao Xie, Zi‐Yi Zhao, Xiao‐Yu Yin   +9 more
wiley   +1 more source

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? [PDF]

, 2003
Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
Garbrecht, M., Heinemann, Volker, Helmberger, T., Lamerz, Rolf, Niebler, K., Schalhorn, A., Schermuly, M. M., Stemmler, J., Stieber, P., Stoffregen, C., Szymala, A. M., Wilkowski, R.   +11 more
core   +1 more source

FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
FXYD3 binds IRF7 via its 60–87aa domain, triggering a cGAS/STING‐mediated positive feedback loop amplified by type I interferon. This sustains JAK2/STAT5 activation, accelerating ICC progression. Targeting FXYD3 with siFXYD3@PEP suppresses tumors and enhances chemotherapy sensitivity. Abstract Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis,
Yan Zhou, Xiaofeng Shen, Shuo Zhang, XiaoHong Pu, Zipeng Xu, Xiang Zhao, Wei Feng, Yuan Liang, Xingtao He, Aihua Yang, Yudong Qiu, Yihang Yuan, Chaobo Chen, Jun Chen   +13 more
wiley   +1 more source

Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207

Molecular Oncology, 2018
Gemcitabine serves as a first‐line chemotherapy agent for advanced pancreatic cancer (PC). However, the molecular basis by which gemcitabine exerts its effects is not well‐established, and the targeted genetic pathways remain unclear.
Lei You, Huanyu Wang, Gang Yang, Fangyu Zhao, Jingcheng Zhang, Ziwen Liu, Taiping Zhang, Zhiyong Liang, Changzheng Liu, Yupei Zhao   +9 more
doaj   +1 more source

Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis, and chemotherapeutic resistance via accumulation of MCL1 [PDF]

, 2018
学位記番号 ...
Ishii, Norihiro, イシイ, ノリヒロ, 石井, 範洋   +2 more
core  

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland, Assenat, Bazhin, Carbone, Chaput, Chen, Chouaib, Danenberg, David, Dyson, El-Deiry, Gallick, Gelovani, Ghansah, Giese, Gil, Gress, Gribben, Hao, Hao, Hao, Henson, Jemal, Kiessling, Kroemer, Kroemer, Kroemer, Levi, Luo, Mi, Moses, Plate, Powis, Powis, Powis, Ravichandran, Ricci, Rodeck, Sarker, Schuler, Semenza, Singh, Spisek, Tani, Vandenabeele, Wang, Wang, Zitvogel, Zitvogel, Zitvogel   +49 more
core   +1 more source